Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Veritone Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 211.6× Veritone Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Veritone Inc for 12 Days on average.
| HALO | VERI | |
|---|---|---|
Market Cap | $12.58B | $59.46M |
Volume | 2,179,278 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $115.22 | $8.39 |
52-Week Low | $61.63 | $0.59 |
Typical Hold Time | 1 Days | 12 Days |
Enterprise Value | $14.49B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Veritone (VERI) trades at $0.58, down 16% today, reflecting ongoing investor concerns despite some positive business developments. The stock shows bearish technical signals with moving averages indicating strong selling pressure, while fundamentals reveal significant challenges with a -117.5% net income margin and consistent quarterly losses. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are offset by ongoing securities litigation investigations.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests substantial upside potential with a $3.75 price target. Key risks include the company's inability to achieve profitability, competitive pressures in AI solutions, and legal uncertainties. The stock presents high-risk speculation with potential for recovery if cost reductions and new partnerships drive meaningful revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
